A High-Throughput Platform for COVID-19 Serodiagnosis, Vaccine Evaluation, and Drug Discovery
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 3R01AI134907-03S2
Grant search
Key facts
Disease
COVID-19Start & end year
20202021Known Financial Commitments (USD)
$699,894Funder
National Institutes of Health (NIH)Principal Investigator
RICARDO RAJSBAUMResearch Location
United States of AmericaLead Research Institution
The University of Texas Medical Branch at GalvestonResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Diagnostics
Special Interest Tags
N/A
Study Type
Unspecified
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
In response to the current COVID-19 pandemic, it is of paramount importance to rapidly diagnoseinfections and to develop countermeasures. This project aims to build a high-throughput platformfor rapid COVID-19 serodiagnosis, vaccine evaluation, and therapeutics development.